67341-01-9

Usage

Uses

N-Boc-DL-Phenylglycinol is a useful intermediate for organic synthesis.

InChI:InChI=1/C13H19NO3/c1-13(2,3)17-12(16)14-11(9-15)10-7-5-4-6-8-10/h4-8,11,15H,9H2,1-3H3,(H,14,16)

Upstream product

• 100-42-5 styrene 
• 73210-14-7 N-chloro-N-sodio-tert-butylcarbamate 
• 126610-76-2 Benzyl-((R)-2-hydroxy-1-phenyl-ethyl)-carbamic acid tert-butyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 20989-17-7 Phenylglycinol 
• 169512-94-1 (+/-)-N-tert-butoxycarbonyl-α-phenylglycine methyl ester 
• 155396-71-7 tert-butyl N-(phenyl(phenylsulfonyl)methyl)carbamate 
• 4530-20-5 BOC-glycine 
• 126568-41-0 Benzyl-((1R,2S,3S)-4-benzyloxy-2,3-bis-methoxymethoxy-1-phenyl-butyl)-amine 
• 591-51-5 phenyllithium 
• 56613-80-0 D-2-phenylglycinol 
• 20989-17-7 (2S)-2-phenylglycinol 
• 2900-27-8 2-(tert-butoxycarbonylamino)-2-phenylacetic acid 
• 150884-50-7 benzaldehyde N-boc imine 

Downstream Products

• 138457-47-3 1-azido-2-phenyl-2-(N-tert-butoxycarbonylamino)ethane 
• 2900-27-8 2-(tert-butoxycarbonylamino)-2-phenylacetic acid 
• 56613-80-0 D-2-phenylglycinol 
• 20989-17-7 (2S)-2-phenylglycinol 
• 476352-85-9 [2-(isoquinolin-7-yloxy)-1-phenyl-ethyl]-carbamic acid tert-butyl ester 
• 86217-38-1 4-phenyl-2-oxazolidinone 
• 552331-34-7 (2S)-[1-(3,5-dibromo-phenoxymethyl)-2-(1H-indol-3-yl)-ethyl]-carbamic acid tert-butyl ester 
• 552331-46-1 (2-hydroxy-1-phenyl-ethyl)-carbamic acid tert-butyl ester 
• 140196-38-9 1,1-dimethyl (2-oxo-1-phenylethyl)carbamate 
• 153923-43-4 C₁₄H₂₁NO₅S 
• 1319741-24-6 (+/-)-tert-butyl [1-phenyl-2-(vinyloxy)ethyl]carbamate 
• 1344151-75-2 C₂₀H₂₃F₂N₃O₃ 
• 1344151-76-3 C₂₅H₃₂F₂N₄O₃ 
• 1344151-77-4 C₂₆H₃₀F₂N₄O₄ 

Relevant academic research and scientific papers

Construction and activity evaluation of novel dual-target (SE/CYP51) anti-fungal agents containing amide naphthyl structure

With the increase of fungal infection and drug resistance, it is becoming an urgent task to discover the highly effective antifungal drugs. In the study, we selected the key ergosterol bio-synthetic enzymes (Squalene epoxidase, SE; 14 α-demethylase, CYP51) as dual-target receptors to guide the construction of novel antifungal compounds, which could achieve the purpose of improving drug efficacy and reducing drug-resistance. Three different series of amide naphthyl compounds were generated through the method of skeleton growth, and their corresponding target products were synthesized. Most of compounds displayed the obvious biological activity against different Candida spp. and Aspergillus fumigatus. Among of them, target compounds 14a-2 and 20b-2 not only possessed the excellent broad-spectrum anti-fungal activity (MIC50, 0.125–2 μg/mL), but also maintained the anti-drug-resistant fungal activity (MIC50, 1–4 μg/mL). Preliminary mechanism study revealed the compounds (14a-2, 20b-2) could block the bio-synthetic pathway of ergosterol by inhibiting the dual-target (SE/CYP51) activity, and this finally caused the cleavage and death of fungal cells. In addition, we also discovered that compounds 14a-2 and 20b-2 with low toxic and side effects could exert the excellent therapeutic effect in mice model of fungal infection, which was worthy for further in-depth study.

Visible-Light-Induced Intermolecular Oxyimination of Alkenes

An intermolecular vicinal O-N difunctionalization reaction of olefins with oxime esters through energy transfer catalysis has been developed.

Identification of Clinical Candidate M2698, a Dual p70S6K and Akt Inhibitor, for Treatment of PAM Pathway-Altered Cancers

Herein, we report the discovery of a novel class of quinazoline carboxamides as dual p70S6k/Akt inhibitors for the treatment of tumors driven by alterations to the PI3K/Akt/mTOR (PAM) pathway. Through the screening of in-house proprietary kinase library, 4-benzylamino-quinazoline-8-carboxylic acid amide 1 stood out, with sub-micromolar p70S6k biochemical activity, as the starting point for a structurally enabled p70S6K/Akt dual inhibitor program that led to the discovery of M2698, a dual p70S6k/Akt inhibitor. M2698 is kinase selective, possesses favorable physical, chemical, and DMPK profiles, is orally available and well tolerated, and displayed tumor control in multiple in vivo studies of PAM pathway-driven tumors.

Organoiodine-Catalyzed Enantioselective Intermolecular Oxyamination of Alkenes

Metal-free, catalytic enantioselective intermolecular oxyamination of alkenes is realized by use of organoiodine(I/III) chemistry. The protocol is applicable toward aryl- and alkyl-substituted alkenes with high enantioselectivity and electronically controlled regioselectivity. The oxyaminated products can be easily deprotected in one step to reveal free amino alcohols in high yields without loss of enantioselectivity. A key to our success is the discovery of a virtually unexplored chemical entity, N-(fluorosulfonyl)carbamate, as a bifunctional N,O-nucleophile.

Aryl olefin azole derivative as well as preparation method and application thereof

The invention belongs to the technical field of medicines, and relates to an aryl olefin azole derivative shown in a general formula I, stereoisomers thereof and pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof, and substituent groups Ar, R and X have definitions given in the specification. The invention also relates to a method for preparing the compound as shown in the general formula I, a medicinal composition containing the compound and application of the compound and the medicinal composition in preparation of medicines for treating and preventing superficial fungal and deep fungal diseases.

COMPLEMENT MODULATORS AND RELATED METHODS

The present disclosure presents compounds and compositions that interact with complement components. Some compounds inhibit complement activity. Included are small molecule compounds and compositions that function as C5 inhibitor compounds. Methods for inhibiting complement activity and methods of treating complement-related indications with the C5 inhibitor compounds and compositions are provided.

Method for preparing beta arylamine

The invention discloses a method for preparing beta arylamine. The method includes mixing an aziridine compound, halogenated aromatic hydrocarbon, an oxidizing agent, a reducing agent and an organic solvent to obtain a mixed solution and obtaining the beta arylamine after reaction. The oxidizing agent is at least one of a mixture of nickel iodide and bipyridine, a mixture of nickel chloride dimethoxyethane and bipyridine and 2,2'-bipyridinium nickel iodide. The reducing agent is at least one of zinc powder, manganese powder, iron powder, cobalt powder, titanium powder, calcium powder and tetrakis(dimethylamino)ethylene. The halogenated aromatic hydrocarbon is at least one of the chlorinated aromatic hydrocarbon, the brominated aromatic hydrocarbon and aryl iodide. An organometallic reagentis not required, the preparation process is simple and reliable and high in yield, and the aziridine compound is wide in selection range.

Late-Stage Isotopic Carbon Labeling of Pharmaceutically Relevant Cyclic Ureas Directly from CO2

A robust, click-chemistry-inspired procedure for radiolabeling of cyclic ureas was developed. This protocol, suitable for all carbon isotopes (11C, 13C, 14C), is based on the direct functionalization of carbon dioxide: the universal building block for carbon radiolabeling. The strategy is operationally simple and reproducible in different radiochemistry centers, exhibits remarkably wide substrate scope with short reaction times, and demonstrates superior reactivity as compared to previously reported systems. With this procedure, a variety of pharmaceuticals and an unprotected peptide were labeled with high radiochemical efficiency.

Selective amidation of unprotected amino alcohols using surfactant-in-water technology: A highly desirable alternative to reprotoxic polar aprotic solvents

A general selective and environmentally friendly method for the formation of amide bonds using a surfactant in water as medium is described. The use of readily available 1-ethyl-3-(3-(dimethylamino)propyl)-carbodiimide (EDC) and hydroxybenzotriazol (HOBt)

Hit-to-lead evaluation of a novel class of sphingosine 1-phosphate lyase inhibitors

Inhibition of sphingosine-1-phosphate lyase has recently been proposed as a potential treatment option for inflammatory disorders such as multiple sclerosis, rheumatoid arthritis, and inflammatory bowel disease. In this report we describe our hit-to-lead evaluation of the isoxazolecarboxamide 6, a high-throughput screening hit (in vitro IC50 = 1.0 μM, cell IC50 = 1.8 μM), as a novel S1P lyase inhibitor. We were able to establish basic structure-activity relationships around 6 and succeeded in obtaining X-ray structural information which enabled structure-based design. With the discovery of 28, enzyme activity was quickly improved to IC50 = 120 nM and cell potency to IC50 = 230 nM. The main liability in the established isoxazolecarboxamide hit series was determined to be metabolic stability. In particular we identified that future lead-optimization efforts to overcome this problem should focus on blocking the N-dealkylation on the secondary amine.